Anixa Biosciences – Consensus Indicates Potential 66.7% Upside

Broker Ratings

Anixa Biosciences with ticker code (ANIX) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 9 and 8.5 calculating the mean target price we have 8.75. Now with the previous closing price of 5.25 this is indicating there is a potential upside of 66.7%. The 50 day moving average now sits at 4.09 and the 200 day moving average is 2.84. The market capitalisation for the company is $143m. Visit the company website at:

Anixa Biosciences, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences in October 2018. Anixa Biosciences was founded in 1982 and is based in San Jose, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index